HK1032049A1 - Beta-carboline compounds - Google Patents

Beta-carboline compounds

Info

Publication number
HK1032049A1
HK1032049A1 HK01102432A HK01102432A HK1032049A1 HK 1032049 A1 HK1032049 A1 HK 1032049A1 HK 01102432 A HK01102432 A HK 01102432A HK 01102432 A HK01102432 A HK 01102432A HK 1032049 A1 HK1032049 A1 HK 1032049A1
Authority
HK
Hong Kong
Prior art keywords
beta
carboline compounds
carboline
compounds
Prior art date
Application number
HK01102432A
Other languages
English (en)
Inventor
Christophe Alain Thurieau
Lydie Francine Poitout
Marie-Odile Galcera
Christophe Philippe Moinet
Thomas D Gordon
Barry A Morgan
Dennis C H Bigg
Jacques Pommier
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of HK1032049A1 publication Critical patent/HK1032049A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
HK01102432A 1998-06-12 2001-04-04 Beta-carboline compounds HK1032049A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9729798A 1998-06-12 1998-06-12
US8918098P 1998-06-12 1998-06-12
PCT/US1999/012874 WO1999064420A1 (en) 1998-06-12 1999-06-08 β-CARBOLINE COMPOUNDS

Publications (1)

Publication Number Publication Date
HK1032049A1 true HK1032049A1 (en) 2001-07-06

Family

ID=26780327

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01102432A HK1032049A1 (en) 1998-06-12 2001-04-04 Beta-carboline compounds

Country Status (22)

Country Link
US (1) US6586445B1 (de)
EP (1) EP1086101B1 (de)
JP (1) JP2002517500A (de)
KR (1) KR20010071461A (de)
CN (1) CN1169808C (de)
AR (1) AR019153A1 (de)
AT (1) ATE229954T1 (de)
AU (1) AU761020B2 (de)
CA (1) CA2335339A1 (de)
CZ (1) CZ20004580A3 (de)
DE (1) DE69904595T2 (de)
DK (1) DK1086101T3 (de)
ES (1) ES2188184T3 (de)
HK (1) HK1032049A1 (de)
HU (1) HUP0302962A2 (de)
IL (1) IL140197A0 (de)
NO (1) NO319532B1 (de)
NZ (1) NZ508765A (de)
PL (1) PL345589A1 (de)
RU (1) RU2233841C2 (de)
TW (1) TWI236477B (de)
WO (1) WO1999064420A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
US6696418B1 (en) 1999-09-01 2004-02-24 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
FR2812546B1 (fr) * 2000-08-01 2008-11-21 Sod Conseils Rech Applic Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US6495589B2 (en) 2000-04-28 2002-12-17 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
US6720330B2 (en) 2000-11-17 2004-04-13 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
FR2818978B1 (fr) * 2000-12-28 2003-02-28 Sod Conseils Rech Applic Modulateurs de canaux sodiques derives de 2-piperidylimidazoles
GB0108337D0 (en) 2001-04-03 2001-05-23 Novartis Ag Organic compounds
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
CZ20033123A3 (cs) * 2001-06-25 2004-11-10 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farmaceutické prostředky, které inhibují proliferaci adenomů hypofýzy
DE10136842A1 (de) * 2001-07-23 2003-02-13 Schering Ag GABA¶A¶-Rezeptor-Modulatoren mit NMDA-antagonistischer Aktivität
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
PA8586801A1 (es) 2002-10-31 2005-02-04 Pfizer Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
BRPI0407052A (pt) 2003-01-27 2006-01-17 Pfizer Inibidores da hiv-integrase, composições farmacêuticas, e métodos para sua utilização
DE602004026289D1 (de) 2003-05-05 2010-05-12 Probiodrug Ag Glutaminylcyclase-hemmer
CN101837127A (zh) 2003-05-05 2010-09-22 前体生物药物股份公司 谷氨酰胺酰基和谷氨酸环化酶效应物的应用
WO2004113300A1 (ja) 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. 新規三環性複素環化合物
WO2005039548A2 (en) 2003-10-15 2005-05-06 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10360793A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AU2005210004B2 (en) 2004-02-05 2010-10-28 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
ATE541835T1 (de) * 2004-02-05 2012-02-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP2007534738A (ja) 2004-04-26 2007-11-29 ファイザー・インク Ｈｉｖインテグラーゼ酵素の阻害剤
WO2005103003A2 (en) 2004-04-26 2005-11-03 Pfizer Inc. Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
DE102004039382A1 (de) 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP1829874B1 (de) 2004-12-22 2014-02-12 Ono Pharmaceutical Co., Ltd. Tricyclische verbindung und deren verwendung
WO2006089053A2 (en) 2005-02-17 2006-08-24 Wyeth Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
JP5035865B2 (ja) * 2005-09-26 2012-09-26 国立大学法人高知大学 Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ菌株の増殖・運動抑制方法
WO2007062175A2 (en) * 2005-11-21 2007-05-31 Amgen Inc. Spiro-substituted tricyclic heterocycles cxcr3 antagonists
US7879859B2 (en) * 2005-11-21 2011-02-01 Merck Sharp & Dohme Corp. Diagnosis and treatment of type 2 diabetes and other disorders
CN101346375B (zh) * 2005-11-23 2013-04-10 阿罗斯药物有限责任公司 调节门离子通道用组合物和方法
US20080004306A1 (en) * 2006-04-10 2008-01-03 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
CA2693214A1 (en) * 2007-07-19 2009-01-22 Merck Sharp & Dohme Corp. Beta carboline derivatives as antidiabetic compounds
SG10201703086VA (en) * 2008-10-17 2017-05-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
WO2010051177A1 (en) * 2008-10-29 2010-05-06 Merck Sharp & Dohme Corp. Triazole beta carboline derivatives as antidiabetic compounds
TW201028414A (en) 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
CN102844029A (zh) * 2009-12-28 2012-12-26 奥迪欧医药设备有限公司 用于治疗听力损伤和眩晕的β-咔啉
CN102695414A (zh) 2010-01-15 2012-09-26 默沙东公司 作为抗糖尿病化合物的噁二唑β-咔啉衍生物
KR101256588B1 (ko) * 2010-02-17 2013-04-19 부산대학교 산학협력단 베타-카르볼린 알칼로이드를 함유하는 멜라닌 생성 촉진용 조성물
KR101784284B1 (ko) * 2011-03-28 2017-10-11 에스제이티 몰레큘라 리서치, 에스.엘. 대사증후군 치료 화합물
CN105837569B (zh) * 2016-04-29 2017-12-26 华南农业大学 一种骆驼蓬碱噁唑啉类化合物及其制备方法和应用
CN107118212B (zh) * 2017-05-26 2019-12-03 广西师范大学 1-吡啶-6-甲氧基-9-(3-碘苄)-β-咔啉、合成和应用
CN107163041B (zh) * 2017-05-26 2019-06-21 广西师范大学 一种β-咔啉化合物及其合成方法和应用
CN106995440B (zh) * 2017-05-26 2019-09-03 广西师范大学 1-吡啶-6-甲氧基-9-(2，3，4，5-四氟苄基)β-咔啉化合物及其合成方法和应用
CN107141285B (zh) * 2017-05-26 2019-12-03 广西师范大学 1-吡啶-6-甲氧基-9-甲基苄-β-咔啉及其合成和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378803A (en) * 1987-12-11 1995-01-03 Sterling Winthrop Inc. Azole-fused peptides and processes for preparation thereof

Also Published As

Publication number Publication date
ES2188184T3 (es) 2003-06-16
RU2233841C2 (ru) 2004-08-10
IL140197A0 (en) 2002-02-10
DE69904595D1 (de) 2003-01-30
CN1169808C (zh) 2004-10-06
DK1086101T3 (da) 2003-03-31
AR019153A1 (es) 2001-12-26
CA2335339A1 (en) 1999-12-16
ATE229954T1 (de) 2003-01-15
NO20006268D0 (no) 2000-12-11
DE69904595T2 (de) 2003-11-27
US6586445B1 (en) 2003-07-01
EP1086101B1 (de) 2002-12-18
WO1999064420A1 (en) 1999-12-16
PL345589A1 (en) 2001-12-17
JP2002517500A (ja) 2002-06-18
NZ508765A (en) 2003-10-31
AU4553699A (en) 1999-12-30
AU761020B2 (en) 2003-05-29
EP1086101A1 (de) 2001-03-28
NO319532B1 (no) 2005-08-29
NO20006268L (no) 2001-01-29
CZ20004580A3 (cs) 2001-12-12
HUP0302962A2 (hu) 2003-12-29
CN1308632A (zh) 2001-08-15
TWI236477B (en) 2005-07-21
KR20010071461A (ko) 2001-07-28

Similar Documents

Publication Publication Date Title
HK1032049A1 (en) Beta-carboline compounds
GB9804734D0 (en) Compounds
GB9804175D0 (en) Compounds
GB9818689D0 (en) Compounds
GB9818881D0 (en) Compounds
GB9821977D0 (en) Compounds
GB9809823D0 (en) Compounds
GB9810876D0 (en) Compounds
GB9801712D0 (en) Compounds
GB9812522D0 (en) Compounds
GB9822140D0 (en) Compounds
GB9809217D0 (en) Compounds
GB9805447D0 (en) Compounds
GB9821750D0 (en) Compounds
GB9806701D0 (en) Compounds
GB9807756D0 (en) Compounds
GB9808813D0 (en) Compounds
GB9806690D0 (en) Compounds
GB9806379D0 (en) Compounds
GB9809972D0 (en) Compounds
GB9809988D0 (en) Compounds
GB9805446D0 (en) Compounds
GB9812140D0 (en) Compounds
GB9805133D0 (en) Compounds
GB9814649D0 (en) Compounds

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20060608